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involved with tumor target recognition (Farag et al Blood, 2002). In
particular, AML and Neuroblastoma are NK sensitive pediatric
tumors. CB is limited by the absence of available donor effector
cells (NK, CTL, LAK and NKT cells) for infusion after UCBT
(Cairo et al Transfusion, 2005). We demonstrated the ability to EvE
CB in short-term culture with IL-2, IL-7, IL-12 and anti-CD3
with increased CD3-/16/56dim and bright subsets expressing
KIR3DL1, KIR2DL2, KIR2DL1/S1 and CD94/NKG2a with in-
creased NK and LAK cytotoxicity (Ayello/Cairo et al BBMT,
2006). In this study, we compared short-term culture (48 hrs) with
prolonged cultures (4-10 days) on expansion of NK cells expressing
NCR, KIR, NKG2, lytic ability and mechanisms of tumor lysis.
Rethawed CB cells were cultured 2-10 days with anti-CD3 (50
ng/ml), IL-2 (5 ng/ml), IL-7 (10 ng/ml) and IL-12 (10 ng/ml)
[ABCY]. NKR expression (KIR2DS4, NKG2D, CD94, NKp46),
intracellular granzyme B and LAMP-1 receptor (CD107a) expres-
sion were determined by ﬂow cytometry. Cytotxcity of EvE effec-
tor CB cells was measured by europium release assay at 20:1 E:T
ratio with tumor targets K562 (NK), Daudi (LAK), Kasumi-1
(AML) and SYSY5Y (neuroblastoma). KIR2DS4 was signiﬁcantly
increased at day 10 vs 2 in ABCY in both CD3-/16/56bright and dim
subsets (16.9	0.4 vs 2.1	0.2% and 22.3	0.3 vs 0.9	0.2%,
p0.001, respectively). C-lectin receptor CD94/NKG2D expres-
sion was increased at day 7 vs 2 (41.4	0.43 vs 23.7	2.0%,
p0.001). NCR expression in CD3-/16/56dim NKp46 subset
was increased at day 7 vs 2 (10.1	0.06 vs 2.62	0.8, p0.001).
Granzyme B expression was increased from day 2 to 10 (25.8	1.7
vs 45.1	1.7%, p0.001). CD107a expression was signiﬁcantly
increased at day 7 vs 2 (12.9 	1.4 vs 69.3	2.2%, p0.001).
Additionally, increased cytotoxicity was demonstrated at day 7 vs 2
with tumor targets K562 (71.5	0.81 vs 53.8	3.9%, p0.001),
Daudi (63.9	0.73 vs 38	1.1%, p0.001), Kasumi-1 (56.6	0.4 vs
31.8	1.8, p0.001) and SYSY5Y (59.5	5.35 vs 32.6	4.9%,
p0.01). In summary, CB MNC may be thawed at time of trans-
plantation, recryopreserved, rethawed at a later date, expanded and
activated up to 10 days to yield viable NK subsets which appear to
be cytolytic against AML and Neuroblastoma and could be poten-
tially used as ACI post UCBT.
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EARLY HEMATOPOIETIC CELLS, INCLUDING MEGAKARYOCYTE PRO-
GENITORS, ARE RECOVERED IN ALDH BRIGHT CELL POPULATIONS
ISOLATED BY CELL SORTING FROM PREVIOUSLY FROZEN UMBILICAL
CORD BLOOD
Deibert, E.1, Gentry, T.1, Foster, S.J.1, Kurtzberg, J.2, Balber, A.E.1
1Aldagen, Inc., Durham, NC; 2Duke University Medical Center,
Durham, NC.
ALDH bright [ALDHbr] cell populations sorted from fresh um-
bilical cord blood [UCB] on the basis of their high aldehyde
dehydrogenase [ALDH] activity are known to include hematopoi-
etic progenitor cells [HPC]. However, neither the hematopoietic
potential of ALDHbr cells recovered from previously frozen UCB,
nor the ability of any ALDHbr cells to generate platelets has been
reported. We have measured hematopoietic [CFC-H] and
megakaryocytic [CFC-M] colony forming cells in ALDHbr and
ALDHdim [depleted of ALDHbr cells] populations from thawed
UCB. Cells were washed, immunomagnetically depleted of cells
expressing glycophorin A and CD14, reacted with ALDE-
FLUOR® for ﬂow cytometric detection of ALDH, and sorted to
yield ALDHbr and ALDHdim populations. ALDHbr cells com-
prised 0.38 	 0.15% [mean 	 SD] of thawed UCB cells. CD34
and CD133 cells comprised 90.9 	 3.1% and 57.7 	 9.4 % of
ALDHbr cells, respectively. CD41 and CD110 cells were 23.4	
11.7% and 1.7 	 3.4 % of the ALDHbr population, respectively.
CFC-H activity was enriched 1116-fold in the ALDHbr population
compared to the ALDHdim population [256 	 104 colonies/1000
cells vs. 0.23 	 0.33 colonies/1000 cells], and 65% of the CHC-H
were recovered in the ALDHbr population. The ratio of erythroid
to myeloid colonies generated from ALDHbr population was 3.7.
Others have shown that most ALDHdim HPCs in fresh UCB are
short term progenitors, whereas earlier long-term culture initiating
cells and cells that establish long-term grafts in NOD-SCID
mouse models are ALDHbr. Consistent with this, we found that
GEMM colonies are about ten times more frequent in ALDHbr
CHC-H [6.6 	 4.5 GEMM /1000 cells] than in ALDHdim [0.6 	
1.2 GEMM/1000 cells] cells from thawed UCB. Furthermore,
CFC-M activity was 2015-fold higher in the ALDHbr population
than the ALDHdim population [60 	 35 colonies/1000 cells vs.
0.03 	 0.02 colonies/1000 cells]. Cells giving rise to large
megakaryocyte colonies, usually considered to be CFC-M with the
most self-renewal potential, were particularly enriched in the AL-
DHbr populations; all the large colonies we detected [38.0 	17.4
large CFC-M/1000 cells] were derived from ALDHbr populations.
The rare CFC-M colonies from ALDHdim cells were small or
non-megakaryocytic. These results suggest that ALDHbr cells re-
covered from thawed, banked UCB could be used to reconstitute
erythroid and myeloid, including megakaryocytic, blood elements
after transplantation.
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PD-1 IS REQUIRED TO INDUCE PERIPHERAL CD8 T CELL TOLERANCE
IN RECIPIENTS OF ALLOGENEIC BONE MARROW TRANSPLANTATION
WITH ANTI-CD154
Haspot, F.1, Fehr, T.1, Hogan, T.1, Honjo, T.2, Sykes, M.1 1BMT/
TBRC, Massachusetts General Hospital, Harvard Medical School, Bos-
ton, MA; 2Department of Immunology and Genomic Medicine, Kyoto
University, Graduate School of Medicine, Yoshida, Kyoto, Japan.
We examined the mechanisms involved in peripheral CD8 T cell
tolerance induced by mixed chimerism achieved with non-myeloa-
blative conditioning with low-dose (3 Gy) total body irradiation
(TBI) and 2mg of anti-CD154 antibody. CD8 T cell tolerance is
CD4 dependent and is characterized by a speciﬁc anergic state
toward donor antigens prior to speciﬁc deletion of donor-reactive
cells. We tested the role of the PD-1 pathway in a model in which
only CD4 peripheral tolerance is required (i.e. TBI 3 Gy and
depleting anti-CD8 mAb Day -1, 2mg of anti-CD154 Day 0
followed by allogeneic BMT) and in a model in which both CD4
and CD8 peripheral tolerance is required (i.e. TBI 3 Gy Day -1
and 2mg of anti-CD154 followed by allogeneic BMT) for the
development of mixed chimerism. PD1-/- (C57BL/6 background)
or C57BL/6 wild-type mice received fully allogeneic bone marrow
cells (B10.A). While WT control mice showed successful mixed
chimerism induction with both regimens, the PD1-/- recipients
failed to develop mixed chimerism unless they were CD8 depleted.
These results indicate that PD1 is required for the tolerance of
peripheral donor-reactive CD8 cells but not for that of CD4 T
cells. We conﬁrmed these results using blocking anti-PD1 and
anti-PD-L1 mAb in WT B6 recipient mice. While control groups
again showed successful engraftment, recipient mice treated with
blocking anti-PD-1 and anti-PDL-1 mAb failed to develop mixed
chimerism unless they were depleted of CD8 cells. Chimeric mice
that were CD8 depleted and received PD-1 blockade accepted
donor skin grafts while rejecting third party grafts. Thus, a func-
tional PD1-PDL1 pathway is critical to achieve donor-speciﬁc
CD8 T cell tolerance in our model.
GVH/GVL
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BLOOD EOSINOPHILIA AS A MARKER OF FAVORABLE OUTCOME AFTER
ALLOGENEIC STEM CELL TRANSPLANTATION
Aisa, Y.1, Mori, T.1, Nakazato, T.1, Shimizu, T.1, Yamazaki, R.1,
Ikeda, Y.1, Okamoto, S.1 1Keio University Hospital, Tokyo, Japan.
Eosinophilia is observed in a variety of systemic disorders includ-
ing acute and chronic graft-versus-host disease (GVHD) after
allogeneic stem cell transplantation (allo-SCT). The clinical
records of 237 adult patients who underwent allo-SCT were ret-
rospectively reviewed. Peripheral complete blood cell counts
(CBCs) had been performed at least two or three times a week until
day 100 in all cases, and white blood cell differentiation was
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evaluated by microscopic examination. Eosinophilia was deﬁned as
a relative eosinophil count greater than 4% on at least one day
within the ﬁrst 100 days after allo-SCT. Eosinophilia was observed
in 135 patients (57%). The cumulative incidence of grades II to IV
acute GVHD was found to be signiﬁcantly higher in patients
without eosinophilia than in those with eosinophilia (68% vs. 43%;
P  0.001). In 15 of 58 (26%) patients with eosinophilia and 41 of
70 (59%) patients without eosinophilia, acute GVHD was resistant
to standard doses of prednisolone and required salvage therapy (P
 0.022). The cumulative incidence of chronic GVHD was sig-
niﬁcantly higher in patients without eosinophilia than in those with
eosinophilia (73% vs. 56%; P  0.011). The cumulative incidence
of relapse in patients with hematologic malignancies was similar
between patients with and without eosinophilia (33% vs. 27%; P
0.438). On the other hand, the cumulative probability of non-
relapse mortality was 10% in patients with eosinophilia, which was
signiﬁcantly lower than that in patients without eosinophilia (31%;
P  0.001), and the estimated overall survival at 3 years was 67%
in patients with eosinophilia, which was signiﬁcantly higher than
that in patients without eosinophilia (51%; P  0.003). Multivar-
iate analysis identiﬁed age above 40 years, high-risk disease, grade
II to IV acute GVHD, sex disparity between patient and donor,
and the absence of eosinophilia as signiﬁcant factors for reduced
overall survival. These data lead us to conclude that eosinophilia
after allo-SCT may serve as a favorable prognostic marker. How-
ever, further prospective studies including detailed cytokine pro-
ﬁling are essential for an understanding of the pathophysiological
mechanisms involved in posttransplant eosinophilia.
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A CRITICAL CONTRIBUTION OF DONOR -173G/C POLYMORPHISM OF
MACROPHAGE MIGRATION INHIBITORY FACTOR GENE TO THE DEVEL-
OPMENT OF CHRONIC GRAFT VERSUS HOST DISEASE
Chang, Y.1, Holler, E.1, Greinix, H.T.2, Dickinson, A.M.3, Wolff, D.4,
Andreesen, R.1, Hildebrandt, G.C.1 1Department of Hematology and
Oncology, University of Regensburg Medical School, Regensburg, Ger-
many; 2Department of Internal Medicine I, Medical University of Vi-
enna, Vienna, Austria; 3School of Clinical and Laboratory Sciences, The
Medical School, Newcastle upon Tyne, United Kingdom; 4Department of
Hematology and Oncology, University of Rostock, Rostock, Germany.
Chronic graft versus host disease (cGVHD) severely impairs the
clinical outcome and life quality after allogeneic stem cell trans-
plantation (allo-SCT). Its pathophysiology is not fully understood,
and treatment often fails. Macrophage migration inhibitory factor
(MIF) is produced by various cell types including T cells, macro-
phages, epithelial cells and shows a broad range of proinﬂamma-
tory properties. A G to C transition at position -173 of the MIF
gene has been associated with the development of various inﬂam-
matory diseases. Here, we assessed the contribution of the minor C
allele to cGVHD development.
Donor-recipient pairs of 405 patients receiving allo-SCT
(matched unrelated donor (URD): n225; matched related donor
(MRD): n180) at four independent centers and surviving 100
days after SCT were genotyped. Stem cells were derived from bone
marrow (n163) or from peripheral blood (n242) and T cell
depletion (TCD) was performed in 30.7% of cases. Mean follow up
was 888	46 days. The C allele (GC or CC genotype) was present
in 29.2% of recipients and 26.7% of donors. No association was
seen between acute GVHD and the G/C polymorphism of either
the donor or the recipient. Overall, 46.8% of all patients developed
cGVHD: 43.1% of patients with a GG genotype donor and 55.4%
of patients when the donor carried a C allele (p0.04). The
incidence of cGVHD was not altered by the patient
s MIF status
(GG: 45.3% vs. GC/CC: 49.1%; p0.6).
In patients receiving URD SCT, the presence of a donor C allele
resulted in an increase in cGVHD development from 47.2 to
63.9% (p0.03). This effect was not seen in MRD SCT (p0.58).
Since T cells are a major source of MIF, we then tested the effect
of TCD on the role of donor MIF in cGVHD development after
URD SCT. cGVHD incidence was signiﬁcantly increased in pa-
tients receiving non-TCD allo-SCT from GC or CC unrelated
donors compared to recipients of GG donor cells (71.1 vs. 52.9%;
p0.045). When TCD was performed, cGVHD occurence was
not affected, independent whether the donor carried the C allele or
not (52.2 vs. 40.0%; p0.2). The presence of a donor C allele
further led to a signiﬁcant increase in treatment related mortality
(TRM) from 6.4 to 28.6% when no TCD was performed
(p0.002), whereas TRM after TCD in both groups ranged be-
tween 31.0 and 32.7%.
Collectively, our data demonstrate a distinct role for donor T cell
derived MIF in the development of cGVHD, which may allow
MIF as a new immunotherapeutic target in future.
27
TREATMENT OF EXPERIMENTAL ACUTE GRAFT-VERSUS-HOST DISEASE
USING EXTRACORPOREAL PHOTOTHERAPY: A NOVEL MURINE MODEL
Gatza, E.1, Rogers, C.E.1, Clouthier, S.G.1, Ferrara, J.L.M.1 1Uni-
versity of Michigan Department of Pediatrics, Ann Arbor, MI.
Extracorporeal phototherapy (ECP) is an emerging therapy for
clinical graft-versus-host disease (GVHD) that exposes a patient’s
peripheral white blood cells (WBCs) to photo-activatable 8-methoxy-
psoralen (8-MOP) and UVA light before re-infusing them. We have
developed a novel murine model that closely mirrors ECP treatment
of clinical GVHD to investigate its mechanism of action. C3H.SW
mice were conditioned with 11Gy total body irradiation and injected
with 5.0106 bone marrow and 0.5106 puriﬁed T cells from either
syngeneic (C3H.SW) or allogeneic (B6-Ly5.2) donors. In order to
model ECP as a treatment strategy rather than as prevention, animals
were not treated until GVHDwas clinically evident 7 days after BMT
and then received 4 weekly infusions with 30.0106 8-MOPUVA
treated splenocytes from similarly transplanted mice. Control mice
were infused with untreated splenocytes, and did not show any dif-
ferences from mice treated with L-15 (data not shown). Infusion of
8-MOPUVA-treated splenocytes into allo-BMT recipients resulted
in signiﬁcantly better day 56 survival (74% vs 42%, p0.0007),
reduced GVHD clinical scores (2.9 vs 5.9, p0.004) and GVHD
histopathology in liver (7.3 vs 13.4), gut (11.4 vs 18.4) and skin (0.6 vs
1.2; all organs p0.03) compared to mice infused with untreated
splenocytes. ECP treated allo-BMT recipients also had signiﬁcantly
better immune reconstitution (p0.01) on day 56, with both total
thymocytes and distribution of thymocyte compartments indistin-
guishable from syngeneic controls. In vitro studies showed that98%
of cells were Annexin within 24h of ECP treatment and experiments
using Ly5 congenic donors demonstrated that ECP treated cells are
undetectable in the thymus and spleen following injection. Because
apoptotic cells are known to induce tolerance in several systems, we
hypothesized that ECP increased the number of T regulatory cells
(Treg). The number of CD4CD25Foxp3 Treg in ECP-treated
allo-BMT recipients was signiﬁcantly increased compared to mice
infused with untreated splenocytes in the thymus (2.5 vs 1.0104,
p0.02) and the spleen (1.8 vs 1.1105, p0.008). We conclude that
4 weekly infusions of ECP treated cells beginning after GVHD
induction signiﬁcantly decreases acute GVHD by all clinical, patho-
logical and cellular parameters and is associated with increased num-
bers of Tregs.
SYN ALLO ALLO
/- ECP No ECP Spl ECP Spl p-value*
Number 15 19 34
Day 56 Analysis:
Survival 100% 42% 74% 0.0007
GVHD Clinical Score 1.10.4 5.90.3 2.90.4 0.004
Pathology
Liver 2.10.9 13.45.5 7.32.5 0.0001
Intestine 7.42.8 18.45.7 11.43.1 0.0003
Skin 0 1.20.7 0.60.6 0.03
Thymic reconstitution
Thymocytes (x106) 12.49.9 2.22.1 7.77.2 0.01
Thymic Treg (x104) 5.12.6 1.00.6 2.51.4 0.02
Spleen Treg (x105) 6.22.9 1.10.4 1.80.1 0.008
* 95% conﬁdence level, AlloECP Spl vs AlloNo ECP Spl
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